ABSTRACT
Coronavirus disease 2019 (COVID-19) is a worldwide public health problem that has attracted much attention due to its clinical findin gs. Measurement of IgG and IgM antibodies is of great importance for researchers and it will help t o develop a new diagnostic and therapeutic method in clinical care. In this cross-sectional study, we aim to measure th e IgG and IgM antibody levels in 401 suspected COVID-19 volunteers. We also measure the time duration for the appearance of IgG and IgM antibodies from the onset of symptoms to sa mpling time. Of 401 participants enrolled in the study, 255 (63.59%) were healthy, 79 (19.70%) were a carrier, 59 (14.71%) were cured and 8 (1.99%) were borderline. Of 142 subjects diagnosed with COVID-19, 41 (28.87%) presented with gastrointestin al (GI) symptoms, 83 (58.45%) had no GI symptoms, and 18 (12.68%) were asymptomatic. According to our findings, the measurement of IgG a nd IgM antibodies will provide the tool for the diagnosis of COVID-19 and significantly boo st research into novel diagnostic and therapeutic approaches.
ABSTRACT
Background: Seeking new specific and effective drugs against Coronavirus Diseases-2019 (COVID-19) is of great importance. This study describes the efficacy of remdesivir with supportive care alone in the treatment of critically sick adult and child COVID-19 patients. Method(s): This study was a one-blind placebo-controlled, randomized clinical trial in adults (aged>=18 years) and children (aged<=12 years) in Iran. Patients were included if they had positive PCR test for SARS-CoV-2 infection, O2 saturation <=88%, and compatible symptoms. All participants received standard care following national treatment guidelines. The treatment group received remdesivir (200 mg IV on day 1 and followed by 100 mg in single daily infusions). The control group received standard care and an identical volume of placebo infusions (Water for injection) for 5 days. For pediatric patients, the intervention group received remdesivir (5mg/kg on the first day and then 5.2 mg/kg on days 2 to 5). Discharge from the hospital within 10 days of first treatment is considered as the primary endpoint of the study. Admission in the intensive care unit (ICU) is considered as original secondary endpoint of the study. Result(s): 141 patients were enrolled and randomly assigned to two group (adults;54 patients in the intervention group vs. 52 patients in the control group, and children;17 patients in the intervention group vs. 18 patients in the control group). The mean time from the first symptoms until the referral to the hospital in adult patients was 5.61 +/- 2.67 day and 4.80+/-1.48 day for intervention and control groups, respectively. The mean time from the first symptoms until death was reported to be significant and was longer for intervention group than the control group (24.83 +/- 11.25 vs. 10.50 +/- 2.42 day;p value=0. 012). For children who received remdesivir, the mean time between admission until death was reported to be significant, as the finding high-lighted a longer time duration for the intervention group (13.55 +/- 0.72 vs. 10.66 +/- 0.57 day;p value=0. Mechanicalanical ventilation was used in 17 patients (100%) and 18 patients (100%) in the intervention and control groups, respectively (p value=0.853). Conclusion(s): Among patients with critical COVID-19, those randomized to a 5-day treatment of remdesivir did have a statistically significant difference in clinical status compared with the control group of both adults and children. Clinical Trial Registration Number: This study is registered in the Iranian Registry of Clinical Trial (No. IRCT 20200405046953N1). Copyright © 2023 Bentham Science Publishers.
ABSTRACT
Introduction: New Coronavirus disease 2019 (COVID-19) has caused serious health problems worldwide. The disease first started in Wuhan, China, and then resulted in thousands of deaths throughout the world. Case Presentation: According to data from involved patients, children and neonates include a small proportion of patients with COVID-19. However, in some cases, hospitalization and even death still may occur. In this case report, we described mortality associated with COVID-19 in two pediatrics from Qom city, Iran. One of them presented with severe symptoms that needed high-flow ventilation and admission to the ICU. Conclusions: The findings of this report confirm that COVID-19 may cause death in pediatrics, like in adults. Timely diagnosis, precise evaluation of clinical symptoms, and effective treatment of COVID-19-infected children can play an important role in reducing mortality rates.